https://www.businesswire.com/news/home/20200817005196/en/Enterprise-Therapeutics-Doses-Subjects-Phase-1-Trial
Enterprise Therapeutics Doses First Subjects in Phase 1 Trial for First-in-Class Cystic Fibrosis Therapy ETD002
ETD002 is a novel TMEM16A chloride channel potentiator
Therapy applicable to all cystic fibrosis patients, independent of genotype
